The human immune system is a complex set of cells and organs that can be adversely affected by drugs, resulting in increased susceptibility to infections, anti-drug antibody reactions, and other forms of immune system disease. Many of the emerging novel therapeutics for human disease are products containing proteins, biopolymers or cell-based therapies, which have considerable potential to induce immunogenicity and immunotoxicity. Thus, it is important to monitor therapeutic candidates for development of unwanted immune responses, such as anti-drug antibodies that can cause allergic or anaphylactic reactions, reduction in therapeutic efficacy, or induction of autoimmunity.

TICRO has the capacity and expertise to evaluate the induction of anti-drug antibody responses to biotechnology and biopharmaceutical therapeutics in animal models.

For more information, please contact:

William Reiley, Ph.D.
Senior CRO Program Manager
(518) 891-3080, ext. 315
TICRO@trudeauinstitute.org